← Back to Search

Antisense Oligonucleotide

QR-1123 Single dose - dose level 1 for Vision Impairment (AURORA Trial)

Phase 1 & 2
Waitlist Available
Research Sponsored by ProQR Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Main
Male or female, ≥ 18 years of age.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights

AURORA Trial Summary

This trial is looking at the safety and effectiveness of a new eye drug given as a single injection or as repeat doses.

Eligible Conditions
  • Vision Impairment
  • Retinitis
  • Retinal Dystrophy
  • Retinal Disease
  • Eye Diseases
  • Retinitis Pigmentosa
  • Tunnel Vision

AURORA Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

AURORA Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence and Severity of non-ocular AEs
Incidence and Severity of ocular AEs
Secondary outcome measures
Assessment of systemic exposure after treatment with QR-1123
Changes in BCVA
Changes in DAC perimetry
+6 more

AURORA Trial Design

6Treatment groups
Experimental Treatment
Group I: Repeat dose cohort 1Experimental Treatment2 Interventions
Double-masked, randomized, sham controlled, Repeat dose cohort. Dose levels will be determined following DMC review of obtained safety and efficacy data.
Group II: QR-1123 Single dose - dose level 5Experimental Treatment1 Intervention
Open label Single dose cohort: dose level 5
Group III: QR-1123 Single dose - dose level 4Experimental Treatment1 Intervention
Open label Single dose cohort: dose level 4
Group IV: QR-1123 Single dose - dose level 3Experimental Treatment1 Intervention
Open label Single dose cohort: dose level 3
Group V: QR-1123 Single dose - dose level 2Experimental Treatment1 Intervention
Open label Single dose cohort: dose level
Group VI: QR-1123 Single dose - dose level 1Experimental Treatment1 Intervention
Open label Single dose cohort: dose level 1

Find a Location

Who is running the clinical trial?

ProQR TherapeuticsLead Sponsor
11 Previous Clinical Trials
286 Total Patients Enrolled
ProQR Medical MonitorStudy DirectorProQR Therapeutics
7 Previous Clinical Trials
166 Total Patients Enrolled
ProQR Clinical Trial ManagerStudy DirectorProQR Therapeutics
3 Previous Clinical Trials
106 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
2019. "A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04123626.
All > Retinitis Pigmentosa
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top